Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:III-326-III-331

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toyoda, Y.
Right arrow Articles by McCully, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyoda, Y.
Right arrow Articles by McCully, J. D.
Related Collections
Right arrow CV surgery: other

(Circulation. 2000;102:III-326.)
© 2000 American Heart Association, Inc.


Myocardial Protection and Vascular Biology

Anti-Stunning and Anti-Infarct Effects of Adenosine-Enhanced Ischemic Preconditioning

Yoshiya Toyoda, MD; Vincenzo Di Gregorio, MD; Robert A. Parker, ScD; Sidney Levitsky, MD; James D. McCully, PhD

From the Division of Cardiothoracic Surgery and Biometrics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.

Correspondence to Dr James D. McCully, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 77 Ave Louis Pasteur, Room 144, Boston, MA 02115.

Background—Adenosine-enhanced ischemic preconditioning (APC) extends the protection afforded by ischemic preconditioning (IPC) by both significantly decreasing infarct size and significantly enhancing post-ischemic functional recovery. In this study, the anti-infarct effects and the anti-stunning effects of APC in contributing to enhanced post-ischemic functional recovery were determined and compared with IPC.

Methods and Results—Sheep (n=96) were subjected to 15, 30, 45, or 60 minutes of regional ischemia and 120 minutes of reperfusion. IPC hearts received 5 minutes of regional ischemia and 5 minutes of reperfusion before ischemia/reperfusion. APC hearts received a bolus injection of adenosine coincident with IPC. Adenosine hearts (ADO) received a bolus injection of adenosine before ischemia/reperfusion. Regional ischemia (RI) hearts received no pretreatment. Infarct size/area at risk was determined by tetrazolium staining. Regional myocardial function was determined by sonomicrometry. Segment shortening after 15 minutes of ischemia in which no infarct was incurred was 32.1±10.6% in RI, 70.6±8.5% in IPC, and 77.4±6.0% in APC hearts. Segment shortening after 30 minutes of ischemia was 60.7±6.3% in APC hearts (P<0.05 versus RI, ADO, IPC) but was <37% in all other groups. Infarct size/area at risk after 30 and 60 minutes of ischemia was, respectively, 25.8±5.7% and 49.8±6.0% in RI, 12.9±3.0% and 29.2±5.0% in ADO, 11.6±2.4% and 24.6±2.7% in IPC, and 5.1±1.6% and 12.4±2.0% in APC hearts (P<0.05 versus RI, ADO, IPC).

Conclusions—APC and IPC exhibit anti-infarct and anti-stunning effects in the ovine heart, but these effects are rapidly diminished with IPC. APC significantly extends these effects, providing for significantly enhanced infarct size reduction and post-ischemic functional recovery (P<0.05 versus IPC).


Key Words: adenosine • myocardial infarction • stunning, myocardial • ischemia • reperfusion




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
R. Faro, Y. Toyoda, J. D. McCully, P. Jagtap, E. Szabo, L. Virag, C. Bianchi, S. Levitsky, C. Szabo, and F. W. Sellke
Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor
Ann. Thorac. Surg., February 1, 2002; 73(2): 575 - 581.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. Narayan, R. M. Mentzer Jr., and R. D. Lasley
Annexin V staining during reperfusion detects cardiomyocytes with unique properties
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1931 - H1937.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. Stadler, J. Phillips, Y. Toyoda, M. Federman, S. Levitsky, and J. D. McCully
Adenosine-enhanced ischemic preconditioning modulates necrosis and apoptosis: effects of stunning and ischemia-reperfusion
Ann. Thorac. Surg., August 1, 2001; 72(2): 555 - 563.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. McCully, Y. Toyoda, M. Uematsu, R. D. Stewart, and S. Levitsky
Adenosine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H591 - H602.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Ninomiya, H. Otani, K. Lu, T. Uchiyama, M. Kido, and H. Imamura
Enhanced IPC by activation of pertussis toxin-sensitive and -insensitive G protein-coupled purinoceptors
Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1933 - H1943.
[Abstract] [Full Text] [PDF]